113092-96-9 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
6-BROMO-2-CHLORO-3-METHYLQUINOLINE is used as a building block in the synthesis of pharmaceuticals and agrochemicals for its ability to contribute to the development of new drugs and pesticides. Its unique structure allows for the creation of a variety of compounds with potential therapeutic and pesticidal properties.
Used in Antiviral, Antibacterial, and Antiparasitic Drug Development:
6-BROMO-2-CHLORO-3-METHYLQUINOLINE is used as a potential candidate for drug development due to its antiviral, antibacterial, and antiparasitic activities. Its ability to inhibit the growth and replication of various pathogens makes it a valuable compound in the search for new treatments for infectious diseases.
Used in Research and Development:
6-BROMO-2-CHLORO-3-METHYLQUINOLINE is used as a research tool in the study of biological and chemical processes. Its unique structure and properties make it a valuable compound for understanding various mechanisms and interactions in biological systems, contributing to the advancement of scientific knowledge and the development of new technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 113092-96-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,0,9 and 2 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 113092-96:
(8*1)+(7*1)+(6*3)+(5*0)+(4*9)+(3*2)+(2*9)+(1*6)=99
99 % 10 = 9
So 113092-96-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H7BrClN/c1-6-4-7-5-8(11)2-3-9(7)13-10(6)12/h2-5H,1H3
113092-96-9Relevant academic research and scientific papers
INHIBITORS OF FATTY ACID AMIDE HYDROLASE
-
Paragraph 1037, (2016/01/15)
The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
